FDA Approves Ruxience (rituximab-pvvr) for Adult NHL, CLL, Some Auto-Immune Conditions
ACS Launches Geriatric Surgery Verification Program
CMS Proposes CY 2020 & 2021 New Home Infusion Therapy Benefit
ACCC Summary of RO Model Highlights Key Considerations
Administration Withdraws Proposed Drug Rebate Rule
CMS Releases Proposed Radiation Oncology Model Rule
FDA Approves Selinexor for Multiple Myeloma
FDA Approves Daratumumab in Combo for Multiple Myeloma Ineligible for ASCT
FDA Approves Bevacizumab-bvzr (Zirabev™) Avastin Biosimilar
Senate HELP Committee Adds More Drug Pricing Reform Measures to S.1895
President Trump Signs Executive Order Requiring Healthcare Price Disclosure
FDA Approves Pembrolizumab for Metastatic SCLC
FDA Approves Biosimilar Trastuzumab-anns for All Approved Herceptin Indications
ACCC Joins In Comment Letter on Medicare NGS NCD
ACCC Joins In Support for S. 946, Legislation to Improve Access to Clinical Trials
FDA Approves Polatuzumab Vedotin-piiq + BR for Diffuse Large B-Cell Lymphoma
MA Prior Auth Bill Would Simplify Process; Increase Transparency
CMS Issues RFI on Reducing Administrative Burden
Annual Cancer Report to the Nation: Overall Cancer Mortality Decline Continues
FDA Approves Lenalidomide in Combination for Follicular and Marginal Zone Lymphoma
FDA Approves Alpelisib for Metastatic Breast Cancer
FDA Approves Ruxolitinib for Acute Graft-Versus-Host Disease
Radiation Oncology APM: Sooner or Later?
Administration Slows Timeline for IPI, Rebate Regulatory Action
Verma: CAR-T NCD "New Ground" for CMS, Agency Needs More Time
CMS Releases Finalized Medicare Advantage & Part D Rule
FDA Approves Venetoclax Plus Obinutuzumab for CLL and SLL
FDA Approves Avelumab Plus Axitinib for Advanced RCC
FDA Issues Final Guidance to Manufacturers on Biosimilars' Pathway to Interchangeability
FDA Approves Ramucirumab for HCC
